Chemistry, History, and Overview
The origin of ergot alkaloids in the fungus Claviceps purpurea, the historical consequences of ergotism, and the structural feature that explains the class’s broad receptor activity
Ergot alkaloids are derived from a fungus that grows on grain, and their pharmacological history stretches from medieval epidemics to modern obstetric wards and neurology clinics. Understanding where these drugs come from and how their shared chemistry produces wide receptor activity sets the foundation for every clinical application in this chapter.
Ergot alkaloids originate from Claviceps purpurea, a fungus that infects rye and other cereal grains. The fungus replaces the grain kernel with a dark, hard structure called a sclerotium, which concentrates a mixture of alkaloid compounds. When contaminated grain was milled into flour and consumed, the alkaloids entered the human body in quantities sufficient to produce dramatic physiological effects.
This contamination was the cause of epidemic ergotism, a disease that swept through grain-dependent populations in medieval Europe and continued to appear sporadically into the early twentieth century. Modern grain inspection and storage practices have made epidemic ergotism a historical phenomenon in developed countries, but the pharmacology of the alkaloids responsible for it became the foundation of an important drug class.
Epidemic ergotism appeared in two distinct clinical forms, each reflecting different pharmacological consequences of alkaloid exposure. Gangrenous ergotism, historically called St. Anthony’s Fire, was characterized by intense burning pain in the extremities followed by dry gangrene of the fingers, toes, and limbs. The mechanism was sustained peripheral vasoconstriction severe enough to produce ischemia and tissue death. Victims described the sensation of fire in their limbs as circulation was progressively cut off.
Convulsive ergotism, the second form, was characterized by seizures, muscle spasms, and neurological symptoms reflecting direct effects on the central nervous system. Both forms could affect the same population, and the predominant form in any given outbreak appeared to depend on the specific alkaloid mixture in the contaminated grain as well as nutritional factors in the affected population.
All clinically active ergot alkaloids share a common structural core — the lysergic acid backbone. This tetracyclic ring system resembles the molecular shapes of multiple neurotransmitters simultaneously, which is why ergot alkaloids can bind to serotonin receptors, dopamine receptors, and alpha-adrenergic receptors within the same molecule. No other clinical drug class achieves this breadth of receptor engagement from a single structural template.
The clinical derivatives differ from one another primarily in the substituents attached to this core. These modifications shift the balance of receptor binding affinities — one derivative may be predominantly dopaminergic, another predominantly vasoconstrictor, another primarily uterotonic — but all retain the capacity for activity at multiple receptor families to some degree. The lysergic acid backbone is the pharmacological reason this class produces such diverse effects across organ systems.
The lysergic acid backbone structurally mimics serotonin, dopamine, and norepinephrine simultaneously. This single chemical feature explains why ergot alkaloids are not selective drugs — they engage multiple receptor families at once. Every clinical effect and adverse effect in this chapter traces back to this structural reality.
